Project objectivesEvaluation of the role of the drug Upadacitinib, an inhibitor of the Jak-Stat pathway, in the cellular and molecular mechanisms associated with pain with reference to the possible involvement of the BDNF molecule. In detail, the effect of Upadacitinib will be evaluated on glial cells differentiated from monocytes alone and in coculture with immortalized neuronal cells, macrophages and cells deriving from the synovium of patients suffering from rheumatoid arthritis. |
Start and end date |
July 2022-December 2024 |
Project Manager |
Prof. Roberto Giacomelli |
Coordinating institution of the project |
Campus-Biomedical University Polyclinic Foundation |
Funding source(s). |
Non-profit study funded by Abbvie |